IIQ.AU Inoviq Ltd
- Market cap
- AUD 19.0M
- P/E
- -
- P/B
- 1.01x
- ROE
- -39.7%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IIQ.AU undervalued?
Graham numberThe Graham number of Inoviq Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inoviq Ltd fundamental analysis
9 of 21 checks passedROE 0/2
Low return on equity (-39.7%), below 10%.
ROA 0/1
Return on assets (-36.7%) is below the industry median (-0.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (8.8%) is above the industry median (-1.5%).
Revenue Growth 1/2
Revenue grew 2.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (1.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.0x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Inoviq Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasiv…
Full company profileInoviq Ltd financial statements
Inoviq Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 44.0K | 62.4K | 8.73K | 98.4K | 1.27M | 277K | 398K | 535K | 1.82M | 432K |
| Gross Profit | -8.01K | -889K | -193K | -150K | -2.21M | -1.88M | -1.04M | 454K | -1.56M | -975K |
| Operating Income | -2.50M | -2.14M | -2.30M | -2.90M | -10.1M | -9.00M | -10.4M | -7.80M | -10.6M | -9.67M |
| EBITDA | -2.48M | -1.86M | -2.30M | -2.90M | -5.78M | -19.4M | -9.08M | -6.10M | -5.96M | -8.34M |
| Net Income | -2.60M | -1.82M | -1.72M | -3.25M | -11.2M | -18.2M | -8.97M | -6.55M | -6.93M | -7.51M |
| EPS | -0.14 | -0.08 | -0.05 | -0.07 | -0.14 | -0.20 | -0.10 | -0.07 | -0.06 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 727K | 1.45M | 7.63M | 7.37M | 33.5M | 30.8M | 21.5M | 21.7M | 18.5M | 20.5M |
| Total Liabilities | 469K | 323K | 492K | 899K | 4.46M | 2.49M | 1.89M | 1.72M | 1.74M | 1.56M |
| Shareholders' Equity | 258K | 1.13M | 7.13M | 6.48M | 29.1M | 28.3M | 19.6M | 20.0M | 16.7M | 18.9M |
| Cash & Short-term Investments | 667K | 1.45M | 7.56M | 7.33M | 5.00M | 15.4M | 7.81M | 9.23M | 6.52M | 9.35M |
| Total Debt | - | - | - | - | 1.26M | 999K | 731K | 777K | 376K | 289K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.38M | -1.97M | -1.57M | -2.54M | -5.26M | -6.06M | -7.02M | -4.32M | -4.66M | -6.38M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 423K | 786K | 412K | 292K | 174K | 104K | 168K |
| Free Cash Flow | -2.38M | -1.97M | -1.57M | -2.54M | -6.05M | -6.47M | -7.32M | -4.50M | -4.77M | -6.55M |
| Ratios | ||||||||||
| ROE | -1,009.6% | -160.7% | -24.1% | -50.2% | -38.4% | -64.3% | -45.7% | -32.8% | -41.5% | -39.7% |
| ROA | -358.3% | -125.0% | -22.5% | -44.1% | -33.3% | -59.1% | -41.7% | -30.2% | -37.6% | -36.7% |
| Net Profit Margin | -5,914.8% | -2,911.0% | -19,670.9% | -3,306.8% | -877.3% | -6,575.0% | -2,252.4% | -1,224.8% | -381.9% | -1,737.1% |
| Debt to Equity | - | - | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inoviq Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 265K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Dec 1, 2020.
Who owns Inoviq Ltd
- Insiders 33.95%
- Institutions 7.00%
- Public & others 59.05%
- Shares outstanding 141M
- Free float 117M
Inoviq Ltd company profile
- Company name
- Inoviq Ltd
- Ticker
- IIQ.AU
- ISIN
- AU0000196149
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- June
- Address
- 23 Normanby Road, Notting Hill, VIC, Australia, 3168
- Phone
- 61 3 9548 7586
- Website
- inoviq.com
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Inoviq Ltd management
4- Dr. Leearne Maree Hinch B.Sc., B.V.M.S., M.B.A., M.R.C.V.S.Chief Executive Officer
- Mr. Mark Edwards BACC, C.A.CFO & Company Secretary
- Dr. Rebecca Lim B.Sc., Ph.D.Chief Scientific Officer
- Dr. Emma Ball B.Sc., M.B.A., Ph.D.Chief Commercial Officer